Leukemic Cell Reprogramming via OSKM Factors and Small Molecules
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for reprogramming somatic cells into induced pluripotent stem cells (iPSCs) face challenges, particularly in efficiently reprogramming leukemic cells, which often undergo apoptosis and are difficult to convert due to genetic and epigenetic modifications, and there is a lack of effective broad-spectrum therapies for leukemia.
Innovation Solution
The use of reprogramming factors Oct-4, Sox-2, Klf4, and c-Myc (OSKM) is employed to initiate apoptosis in leukemic cells in-vivo or in-vitro by introducing these factors as cDNA, mRNA, or protein, using methods like virus infection, recombinant protein transfection, or vector electroporation, and small molecules such as forskolin, VPA, CHIR99021, RepSox, tranylcypromine, and TTNPB to promote the reprogramming process and induce apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If reprogramming factors OSKM are introduced into leukemic cells to induce reprogramming, then the reprogramming process is initiated, but majority of leukemic cells undergo apoptosis due to genetic and epigenetic modifications
Solution Approach 1:
The patent applies preliminary action by introducing small molecules (such as VPA, CHIR99021, forskolin) before or during the reprogramming factor introduction to pre-condition the leukemic cells. These small molecules modify the epigenetic state and signaling pathways in advance, making the cells more receptive to reprogramming and reducing apoptotic responses when OSKM factors are introduced.
Solution Approach 2:
The patent employs parameter changes by adjusting chemical parameters through small molecule additions. Specifically, VPA (valproic acid) modifies histone deacetylase activity, CHIR99021 activates Wnt signaling, and forskolin activates cAMP pathways. These parameter changes in the cellular environment create favorable conditions for reprogramming while minimizing apoptosis.
2Productivity
If virus infection or lentivirus is used to promote expression of reprogramming factors, then reprogramming efficiency is improved, but mutation rate of somatic cells increases and genome integration occurs
Solution Approach 1:
The patent extracts the reprogramming function from viral vectors and implements it through small molecules that do not integrate into the genome. By taking out the genetic material delivery mechanism and replacing it with small molecule-mediated epigenetic modulation, the method achieves reprogramming without the harmful effects of viral integration and mutation.
Solution Approach 2:
The patent introduces small molecules as intermediaries between the external environment and the cell's reprogramming machinery. These small molecules (VPA, CHIR99021, forskolin) act as mediators that modulate epigenetic states and signaling pathways without requiring direct genetic modification, thus avoiding viral vector-related mutations while still enabling efficient reprogramming.
3Reliability
If multiple transfections or passages are required to obtain iPSCs without vectors, then safety is improved, but time consumption and technical difficulty increase
Solution Approach 1:
The patent merges multiple functions into a single treatment protocol: small molecules simultaneously enhance reprogramming efficiency, reduce apoptosis, and eliminate the need for multiple passages or transfections. By combining epigenetic modulation (VPA), Wnt pathway activation (CHIR99021), and cAMP pathway activation (forskolin) in one protocol, the method achieves vector-free iPSC generation in a single step, saving time while maintaining safety.
Data Source
AI summary
The present invention provides a method for treating leukemia utilizing somatic cell reprogramming. The method includes a step of introduction of somatic cell reprogramming inducing factors Oct-4, Sox-2, Klf4 and c-Myc (OSKM for short) into leukemic cells or a step of utilizing small reprogramming molecules in in-vitro culture. It promotes leukemic cells to initiate process of somatic cell reprogramming in order to induce apoptosis and finally purpose of eliminating leukemic cells in-vivo or in-vitro is achieved. It provides new ideas and methods for clinical treatment of leukemia in the future.